The past two weeks have offered more definitive information on Nilotinib (Tasigna), a drug already approved for treatment of leukemia, as a potential treatment for Parkinson’s disease (PD) symptoms. On December 16, JAMA Neurology published the results of a Phase II safety trial ― a study that tests the effectiveness of a drug or treatment in a larger group of people. Study findings revealed that Nilotinib had more adverse events than the placebo (a pill not containing an active drug) but was reasonably safe.
Parkinson's Today Blog
Donna Hood, PhD, Chair of Division of Nursing and Tara Haskins, PhD, Associate Professor of Nursing at Louisiana Tech University are Parkinson’s Foundation Nurse Faculty Award recipients who received grant funding to launch The Parkinson Resource Center at Louisiana Tech University.
Parkinson’s Foundation Research Advocates were the first people with Parkinson’s disease (PD) to help guide the grant review process for the Department of Defense (DoD) Parkinson’s Research Program. The program supports research to understand, prevent, diagnose and treat Parkinson’s disease.
Not sure what to get your loved one with Parkinson’s disease (PD) for an upcoming holiday or birthday?
Senator Johnny Isakson (R-GA), Senior United States Senator from Georgia will retire from his 45 years in public office on December 31, 2019. The Parkinson’s Foundation is grateful for his longtime commitment to our community, championing Parkinson’s research toward a cure.
Senator Isakson announced his own Parkinson’s diagnosis in 2015, along with his commitment to fight the disease.
At the Parkinson's Foundation, one of the ways we make life better for people living with Parkinson’s disease (PD) is through research. Every day, your generous donations help us fund cutting-edge PD research initiatives and support scientists working on the causes and treatments for Parkinson’s that could one day lead to a breakthrough.
In this Neuro Talk, our Chief Scientific Officer, James Beck, PhD, walks us through the research we’re supporting right now and how your support goes a long way at the Parkinson's Foundation.
People with Parkinson’s disease (PD) and their caregivers frequently report cognitive decline as one of their greatest concerns. Commonly described in terms of mild cognitive impairment (PD-MCI) and Parkinson’s disease dementia (PDD), it is estimated that 30 percent of people with Parkinson’s do not develop dementia as part of the disease progression. Research shows that those with PD-MCI are at increased risk for progression to Parkinson’s dementia.
Over the next three years the Parkinson’s Foundation will invest more than $50 million to Parkinson’s disease (PD) research and clinical care. At the heart of our research initiatives are scientists and researchers who have received Foundation awards to improve our understanding of Parkinson’s, which will ultimately lead us to a cure.